gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Finaly analyzes of biweekly schedule of pegylated liposomal doxorubicin (PLD) in 64 heavily pretreated patients with relapsed ovarian cancer (ROC)

Meeting Abstract

  • corresponding author presenting/speaker Jalid Sehouli - Universitätsklinikum, Jena, Berlin, Deutschland
  • Guelten Oskay-Oezcelik - Charité Universitätsklinikum, Berlin
  • Joshua Kuehne - Charité Universitätsklinikum, Berlin
  • Hans Huindenburg - NOGGO, Berlin
  • Peter Klare - NOGGO, Berlin
  • Georg Heinrich - NOGGO, Berlin
  • Barbara Schmalfeldt - Technische Universität, München
  • Heinrich Mertens - NOGGO, Berlin
  • Oumar Camara - Universitätsklinikum, Jena
  • Werner Lichtenegger - Charité Universitätsklinikum, Berlin

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO348

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 20. März 2006

© 2006 Sehouli et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Objectives: Pegylated liposomal doxorubicin (PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions were reported as being the dose-limiting toxicity and have an impact on patients' quality of life (QoL). The primary aim of this study was to optimise the toxicity profile by choosing a biweekly schedule of PLD Furthermore, QoL was investigated. Secondary objective of this study was to evaluate the response rates of this new regimen.

Methods: We performed a multi-institutional phase-II study to analyze the toxicity profile of PLD (20mg/m²/q 14d) in heavily pretreated patients with ROC. Eligibility criteria: ROC, prior treatment with platinum- and taxan, ECOG status 0-2, organ function within normal range. Statistic: 2-Step-Design, in case of a positive first step (n=26): >2 response + < 6 events of PPE (CTC Grade III/IV), a total number of 60 patients must be recruited; power: 80%, p<0.05, based on a 10% reduction of PPE (95%CI).

Results: A total of 64 patients were recruited (10/2001-02/2004). 553 courses (median: 7, range: 1-35) were evaluable. Median age was 59 years (range, 38-81). Patients were generally heavily pretreated: Only 13 of the patients have been in second-line, most of the patients were in third- or fourth-line of chemotherapy. Heamatologic toxicity profile was favourable: only in three patients anaemia grade III and in one patient thrombocytopenia grade III was observed. Ten patients were in fifth-line. Overall, the treatment was well tolerated. 30 patients developed skin toxicities: 18 patients with grade I, 9 with grade II and only 3 patients with grade III. These side effects occurred after a median of 5 courses. Clinical responses were evaluable with radiologic measurements. Two patients achieved complete responses, further five patients achieved partial response and 13 stable disease and 24 progression disease as best response criteria. The progression-free survival for these heavily pretreated patients was median 4.3 months (range, 0.5-22.3 months) The overall survival was median 18.2 months (range, 1.4-34 months).

Conclusions: Based on our results the new biweekly schedule seems to be an effective and well tolerated regime for patients with heavily pretreated relapsed ovarian cancer.